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targeting CD19 are highly active against B cell malignancies,
but it is unknown whether any of the costimulatory domains
incorporated in the CAR have superior activity to others.
Because CD28 and 4-1BB signaling activate different path-
ways, combining them in a single third-generation (3G)
CAR may overcome the limitations of each individual
costimulatory domain. We designed a clinical trial in which
two autologous CD19-specific CAR-transduced T cell prod-
ucts (CD19.CARTs), 2G (with CD28 only) and 3G (CD28
and 4-1BB), were infused simultaneously in 16 patients
with relapsed or refractory non-Hodgkin’s lymphoma. 3G
CD19.CARTs had superior expansion and longer persistence
than 2G CD19.CARTs. This difference was most striking
in the five patients with low disease burden and few circu-
lating normal B cells, in whom 2G CD19.CARTs had
limited expansion and persistence and correspondingly
reduced area under the curve. Of the 11 patients with
measurable disease, three achieved complete responses and
three had partial responses. Cytokine release syndrome
occurred in six patients but was mild, and no patient
required anti-IL-6 therapy. Hence, 3G CD19.CARTs
combining 4-1BB with CD28 produce superior CART
expansion and may be of particular value when treating
low disease burden in patients whose normal B cells are
depleted by prior therapy.https://doi.org/10.1016/j.ymthe.2018.09.009.
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A chimeric antigen receptor (CAR) combines the antigen binding
portion of a monoclonal antibody with components of the signaling
machinery of a T cell, most commonly the z (zeta) chain of the
T cell receptor (TCR) complex. Genetic transfer of this construct
into T cells endows them with the ability to bind a surface antigen
in tumor cells, leading to T cell activation and target cell killing.1Molecular Therapy Vol. 26 No 12 DecemberAlthough CARs containing the z-chain alone have cytotoxic activity
in vitro, early clinical studies demonstrated that full activation of these
modified T cells in vivo required the CAR to incorporate additional
elements derived from costimulatory domains such as CD28 or
4-1BB (CD137).2 When these so-called second-generation (2G)
CARs target CD19, they have proved to be highly active against
B cell malignancies.3–19 It is, however, still unknown whether some
costimulatory domains have superior activity to others. For instance,
it is asserted that CD28 may lead to quicker T cell expansion and
faster tumor eradication, and 4-1BB may be associated with longer
persistence and protection from relapse,20 but simultaneous compar-
isons in single individuals have not been reported. Because CD28 and
4-1BB signaling activate different pathways in T cells, combining
them in a single third-generation (3G) CAR may provide added
benefits and overcome the limitations of each individual costimula-
tory domain. It is, however, unknown whether such a combination
of two costimulatory endomains in a 3G vector will produce more
rapid, greater, or more persistent CART cell expansion in humans
with CD19+ malignancies than the single costimulatory signals
embedded within 2G CD19-specific CARs. The potential benefits of
3G CARs may be particularly important in the context of a low
burden of disease, since the antigenic stimuli for expansion and
persistence of CAR-T cells will be more limited, and additional2018 ª 2018 The American Society of Gene and Cell Therapy. 2727




(n = 28) p Value
Days in culture 9.9 ± 0.7 10.2 ± 1.2 0.2350
Transduction (% CAR+ cells) 35.0 ± 7.6 71.9 ± 4.8 <0.0001
CD3+ cells (%) 99.3 ± 0.7 98.9 ± 1.1 0.0009
CD3+ CD8+ cells (%) 47.5 ± 17.8 47.6 ± 17.6 0.9289
CD3+ CD45RO+ cells (%) 82.3 ± 19.0 86.4 ± 14.6 0.0276
CD3+ CD127+ (%) 4.0 ± 11.3 2.8 ± 9.2 0.0964
CD4+ CD45RO+ CD62L+ (%) 25.4 ± 12.7 24.1 ± 13.2 0.4477
CD4+ CD45RO+ CCR7+
cells (%)
10.5 ± 10.1 16.4 ± 11.6 <0.0001
CD8+ CD45RO+ CCR7+
cells (%)
6.7 ± 7.8 12.0 ± 9.1 <0.0001
CD3 CD56+ cells (%) 0.4 ± 0.7 0.6 ± 1.1 0.0562
CD3+ CXCR3+ cells (%) 71.9 ± 19.8 66.4 ± 25.7 0.2595
CD3+ CXCR4+ cells (%) 19.3 ± 22.4 14.3 ± 15.2 0.1572
Molecular Therapycostimulation may be required to exceed the threshold of CAR-T cell
activation.
We designed a clinical trial in which two CD19-specific CAR-trans-
duced T cell products (CD19.CARTs) were prepared in parallel
from autologous peripheral blood mononuclear cells (PBMCs). The
first product was retrovirally transduced with a 2G CAR containing
the CD28 costimulatory sequences alone, and the second was trans-
duced with a 3G CAR containing both CD28 and 4-1BB. After
ex vivo expansion, these two products were infused simultaneously
in the same patient. Specific qPCR assays then allowed us to track
each population independently in vivo. This strategy enabled us to
avoid interpatient variability as a confounder and thus to directly
measure the impact of changing costimulatory domains on CAR-T
cell fate in vivo. In this phase 1 study, we treated patients with
CD19+ non-Hodgkin’s lymphoma (NHL), assessed treatment toxicity
and outcome, and compared the fate of each CD19.CART population
in every patient.
We show that simultaneous adoptive transfer of 2G and 3G
CD19.CARTs is feasible. These cells produced clinical responses
and readily manageable toxicities. Cells containing the 3G vector
had superior expansion and longer persistence than the 2G vector,
and this difference was most striking in patients with low disease
burden whose normal CD19+ B cells are depleted by prior therapy,
a group in whom the expansion and persistence of 2G CARTs may
be insufficient for antitumor activity.
RESULTS
Patient Characteristics
We administered CD19.CARTs to 16 NHL patients, 11 with active
disease and five in remission after high-dose therapy and autologous
stem cell transplantation (HDT/ASCT). The characteristics of the
T cell products are summarized in Table 1. Patient characteristics2728 Molecular Therapy Vol. 26 No 12 December 2018are summarized in Tables 2 and 3. All patients with active disease
at the time of CD19.CART infusion had relapsed or persistent disease
after three or more lines of chemotherapy. All of these patients
received lymphodepleting doses of cyclophosphamide (500 mg/m2)
and fludarabine (30 mg/m2) daily for 3 days, finished 24 to 72 hr
before administration of CD19.CARTs. Patients in remission after
ASCT did not receive any additional chemotherapy immediately
prior to CART infusion; all these patients were engrafted and were
treated within 60 days after ASCT.
Characteristics of Infused CD19.CARTs
We manufactured 56 CD19.CARTs from 28 patients. CAR transduc-
tion levels were above the release criterion of >20% in all manufac-
tured T cell products, but the 2G CARTs had an average transduction
level (35% ± 8%) that was approximately half of the 3G CARTs
(72% ± 5%, p < 0.0001). Nevertheless, the same numbers of 2G and
3G CARTs were infused in each patient because total cell numbers
were adjusted for transduction levels. All lines were composed of
>98% CD3+ T cells and each contained a variable ratio of CD4+
and CD8+ T cells, with no overall CD4+ or CD8+ T cell predominance
across the T cell products (Table 1). The majority of CD19.CARTs
were CD45RO+ and lacked CCR7, but a small fraction expressed
central memory-associated phenotypic markers such as CD62L
(Table 1), CD27, and CD28. Notably, the proportion of central mem-
ory CD4+ and CD8+ T cells was increased in 3G compared to
2G CARTs (CD4+CD45RO+CCR7+, 16.4% ± 11.6% versus 10.5% ±
10.1%, p < 0.0001; CD8+CD45RO+CCR7+, 12.0% ± 9.1% versus
6.7% ± 7.8%, p < 0.0001). Natural killer cells (CD3 CD56+) were
not detectable. All products were cytotoxic against CD19+ targets
in vitro, as assessed by 51Cr-release assays, without significant differ-
ences between 2G and 3G CARTs. Cytotoxic activity against CD19
targets was negligible. In vitro experiments have previously shown
that 3G CD19.CARTs have a higher degree of intracellular signaling
activity than 2G CART, although this was not associated with
significant differences in cytotoxic activity between 2G and 3G
CARTs after repeated exposure to targets.21 Twelve patients did not
receive their cell products because they were not eligible for treat-
ment, pursued other treatments, or are awaiting treatment.
CD19.CART Expansion and Persistence
We consistently detected low level molecular signals for both 2G
and 3G CD19.CARTs in the peripheral blood 3 hr after the first
CART infusion, which increased to peak at 2 weeks post-infusion
(Figures 1A and 1B). We observed the highest peak CART expansion
in the patients with active disease (Figure 1A), in all but one of whom
the 3G CARTs expanded (up to 40-fold) more than the 2G CARTs.
At 2 weeks, we detected a mean of 45,383 ± 43,957 copies of the
3G vector/mg of genomic PBMC DNA (gDNA) versus 12,969 ±
18,801 copies of the 2G vector/mg gDNA (p = 0.002 for log area under
the curve [AUC]). In samples with higher transgene levels, we were
able to detect a distinct CAR+ T cell population by flow cytometry
(Figure 1C). The transgene copy numbers then progressively declined
to low but detectable levels by week 6, with the 3G product still being
detected at a higher level than the 2G one. Four patients with active
Table 2. Active Disease Patient Group Characteristics

























1 25.6 75.0 2 0.05 2 SD  6 weeks dead from
progression
2 67 M DLBCL-tFL
R-CHOP,
R-lenalidomide, R-ICE






























3 34.2 70.7 40 0.84 1 NR
alive with
disease
11 17 M LL or ALL
Per COG AALL1131 (arm
A), per COG AALL1331
(blocks 1–2) without
blinatumomab
3 32.4 75.9 40 0.96 1 PR  4 weeks dead from
progression





3 45.3 77.6 40 1.01 2 SD  6 weeks alive without
disease
13 73 F DLBCL-tFL
R, R-CHOP, R-ICE,
R-lenalidomide
3 29 73.2 40 1.25 2 PR  6 weeks alive with
disease




3 41.9 63.5 40 0.93 1 NR
alive without
disease
15 39 M DLBCL
R-CHOP, XRT, GDP,
R-BEAM and ASCT
3 47.9 70.4 40 0.76 1 NR
dead from
progression
16 52 M DLBCL
R-CHOP, R-ICE,
R-GemOx
3 30 69.4 40 1.05 1 CR  6+ weeks alive without
disease
Abbreviations: ASCT, autologous stem cell transplant; BEAM, carmustine, etoposide, cytarabine, melphalan; COG, children’s oncology group protocol; CLL/SLL, chronic lymphocytic
leukemia/small lymphocytic lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CAE, cyclophosphamide, doxorubicin, etoposide; CVP, cyclophosphamide,
vincristine, prednisone; DL, dose level; DLBCL, diffuse large B cell lymphoma; CR, complete response; EPOCH, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin;
ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; FCR, fludarabine, cyclophosphamide, rituximab; hCVAD, hyperfractionated cyclophosphamide, vincristine, cytarabine,
doxorubicin, dexamethasone; GDP, gemcitabine, dexamethasone, cisplatin; GemOx, gemcitabine, oxaliplatin; HiDAC, high-dose cytarabine; ICE, ifosfamide, carboplatin,
etoposide; MACE, methotrexate, doxorubicin, cyclophosphamide, etoposide; LL or ALL, lymphoblastic lymphoma/acute lymphoblastic leukemia; NR, no response; PR, partial
response; R-, rituximab; SD, stable disease; tENMZL, transformed extra nodal marginal zone lymphoma; tFL, transformed follicular lymphoma; UPIN, universal patient identifier
number; XRT, radiation therapy.
www.moleculartherapy.orgdisease received a second infusion of CD19.CARTs that was not pre-
ceded by lymphodepleting chemotherapy. In these patients, we
observed lower peak CART expansion levels compared to those
seen after first infusion, with chemotherapy (Figure 1D), but the
superiority of 3G over 2G vector was retained. In the surviving
patients, molecular signals were still detectable 6 months after the
last CD19.CART infusion, albeit at low levels compared to peak
expansion. In these patients, the 3G CAR signal remained approxi-
mately one log higher than the signal from the 2G CAR (Figure 1A).In patients who were in remission post-ASCT, we observed the
same overall pattern of CART expansion (Figure 1B). Although
peak levels were significantly lower than in patients with active
disease (p < 0.0001 and p = 0.01 for log AUC, in 2G and 3G
CARTs, respectively), the difference between the CD19.CART
products was more striking in this setting: at 2 weeks, we detected
an average of 2,534 ± 2,089 copies of the 3G vector/mg gDNA
versus 13 ± 11 copies of the 2G vector/mg gDNA (p = 0.001 for
log AUC).Molecular Therapy Vol. 26 No 12 December 2018 2729
Table 3. Post-ASCT Patient Group Characteristics









































































Abbreviations: ASCT, autologous stem cell transplant; BCLU, B cell lymphoma unclassifiable with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma;
BEAM, carmustine, etoposide, cytarabine, melphalan; BuGemMel, busulfan, gemcitabine, melphalan; COP, cyclophosphamide, vincristine, prednisolone; COPADM, cyclophospha-
mide, vincristine, prednisolone, cytarabine, doxorubicin, methotrexate; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; DL, dose level; DLBCL, diffuse large B cell
lymphoma; CCR, continued complete response; DHAP, dexamethasone, high-dose cytarabine, cisplatin; EP(O)CH, etoposide, prednisolone, (vincristine), cyclophosphamide,
doxorubicin; I(C)E, ifosfamide, (carboplatin), etoposide; R-, rituximab; LL, lymphoblastic lymphoma; UPIN, universal patient identifier number; XRT, radiation therapy.
Molecular TherapyAcute and Long-Term Toxicities
All infusions were well tolerated. The most frequent treatment emer-
gent adverse events (Table 4) were cytopenias, which were attribut-
able to the administration of lymphodepleting chemotherapy to
patients who had previously been exposed to multiple cytotoxic
agents. Other frequently reported adverse events included hypoalbu-
minemia, hyponatremia, fatigue, and nausea, all transient, which were
likely related to the lymphodepleting chemotherapy, the underlying
lymphoma, or other medications. Notable adverse events included
three instances of grade 2 cytokine release syndrome (CRS),22 mani-
fest by fever, mild tachypnea, and mild hypotension not requiring
vasopressor support or tocilizumab use. Only one patient developed
significant neurotoxicity (incontinence and aphasia), treated with
tocilizumab and dexamethasone, with quick resolution of symptoms.
Three other patients had possible grade 1 CRS.We generally observed
modest increases in inflammatory cytokines at peak CART expansion
compared to baseline levels even in patients with clinical evidence
of CRS (Figure 1E). All patients had baseline B cell lymphopenia
and polyclonal hypogammaglobulinemia resulting from prior treat-
ment, which made assessment of new-onset B lymphopenia due to
CD19.CARTs impractical. Long-term recovery of immunoglobulin
levels continues to be studied in survivors.Clinical Outcomes Post-CD19.CART Infusion
We observed clinical responses in 6 out of 11 patients with active
disease: three complete responses (CRs) and three partial responses
(PRs). Two of the patients (#2 and #4) who had a CR had history2730 Molecular Therapy Vol. 26 No 12 December 2018of indolent NHL transformed to diffuse large B cell lymphoma
(DLBCL); the third (#16) had a de novo high-risk DLBCL. Patients
#2 and #16 (Figures 2 and 3) developed grade 2 CRS but patient #4
(Figure 3) had no clinical evidence of CRS. Patients #2 and #4
have remained in CR for more than 12 months. All three PRs were
short lived. Two patients (#1 and #12) had stable disease after
CART infusion, one of whom (#12) is now in remission on a combi-
nation of rituximab and lenalidomide, to which she previously had
an incomplete response. Four of the five patients treated in CR
after HDT/ASCT have remained in continued CR for more than
9–12 months (Table 3).
We further analyzed antitumor immune responses in the recipients to
seek evidence for newly emergent T cell-mediated immunity to
additional tumor-associated antigens (TAAs). No evidence for such
T cell “antigen spreading” was obtained, since we found no differ-
ences in the frequency of precursor T cells responding to known
TAAs, such as NY-ESO, survivin, PRAME, or MAGE, in peripheral
blood collected before and after CD19.CART infusion (data not
shown).DISCUSSION
We report the first clinical trial directly comparing 2G with 3G
CARTs targeting the same B cell marker (CD19) as a treatment for
lymphoid malignancies. We found that adoptive transfer of 3G
CARTs targeting CD19 is feasible and safe at all dose levels studied,
which are lower than those used in most studies, a fact that may
Figure 1. In Vivo Expansion and Persistence of Infused CD19.CARTs in Peripheral Blood
Expansion was assessed by qPCR and is shown after one infusion of CD19.CARTs in patients with active disease (A), after lymphodepleting chemotherapy, and in remission
post-autologous stem cell transplant (B), without lymphodepleting chemotherapy. (C) Representative flow cytometry data at peak (week 1 to 2) CD19.CART expansion in four
patients (data were acquired in two instruments and thus axes’ scales differ slightly). The flow cytometry staining for the CD19.CARs cannot distinguish between 2G and 3G
CARs, and thus the data represent the combined 2G and 3G circulating CARTs. (D) Summary of expansion data after the first (with lymphodepleting chemotherapy) and
second (without preceding lymphodepleting chemotherapy) infusions for those patients who received two CD19.CART infusions. Data points represent critical post-infusion
intervals after infusion of CD19.CARTs. The lines summarize the mean expansion and persistence (error bars, SEM). (E) Cytokine levels at baseline and during peak CART
expansion in patients who had clinical evidence of possible CRS.
www.moleculartherapy.orghave contributed to limited toxicity. Additionally, we observed that
the inclusion of 4-1BB in addition to CD28 is associated with superior
expansion and persistence. The differences are particularly striking
when these CD19.CARTs are administered to patients with no
measurable disease but who are at high risk for relapse after autolo-
gous stem cell transplantation. These CD19.CARTs can lead to
significant clinical responses, including sustained CRs, in patients
with relapsed or resistant NHL.
The incorporation of costimulatory endodomains into CD19.CAR
molecules is essential to provide proliferative and survival
signals to the CARTs. Although B lymphocytes can express costi-
mulatory ligands, we have previously demonstrated that only 2G
CD19.CARTs containing the CD28 endodomain expanded in vivo
in lymphoma patients receiving two CD19.CART products simul-
taneously, one with and the other without inclusion of CD28.2 It is
now evident that adoptive transfer of T cells bearing 2G
CD19-specific CARs containing either CD28 or 4-1BB costimula-
tory endodomains has remarkable clinical efficacy against B cell
malignancies,8,11,13–19 but the optimal choice of costimulatory
domains in these and other CARs remains controversial. CD28and 4-1BB costimulation have distinct temporal and biochemical
profiles, with CD28 signaling occurring immediately after TCR
engagement, before subsequent activation of the 4-1BB pathway.
While CD28 serves as a docking site for phosphoinositide-3 kinase
(PI3K),23 4-1BB recruits tumor-necrosis-factor-receptor associated-
factor (TRAF) adaptor proteins.24
Recently, Cheng and collaborators25 reported on the clinical re-
sponses and biological correlates of a phase 1 clinical trial treating
seven acute lymphoblastic leukemia patients with the simultaneous
infusion of two 2G products (with either a CD28 or a 4-1BB endodo-
main) targeting CD19. The in vivo expansion pattern of each
CAR-T cell product was variable among patients and no consistent
differences between products were observed. Nonetheless, preclinical
models have demonstrated that inclusion of both CD28 and 4-1BB
endodomains in so-called 3G CARs combine the effects of both
signaling pathways and enhance effector function, expansion,
and survival of CARTs. Indeed, preclinical assessment of these 3G
CD19.CARTs showed higher degree of intracellular signaling activity
compared to the 2G CD19.CARTs.21 In addition, while recent evi-
dence suggests that single costimulation through either CD2826 orMolecular Therapy Vol. 26 No 12 December 2018 2731
Table 4. Adverse Events Associated with Treatment Occurring in Two or
More Patients
Event All Grades Grades 1 and 2 Grade R3
Neutropenia 12 2 10
Leukopenia 12 1 11
Hypoalbuminemia 11 9 2
Anemia 9 7 2
Thrombocytopenia 9 5 4
Lymphopenia 7 1 6
Fatigue 6 6 –
Hypokalemia 5 4 1
Cough 5 5 –
Hypercalcemia 5 5 –
Constipation 4 4 –
Pain 4 3 1
Nausea 4 4 –
Elevated AST 4 3 1
Hyponatremia 4 1 3
Vomiting 3 3 –
Hyperkalemia 3 2 1
Diarrhea 3 2 1
Dyspnea 3 3 –
Hypernatremia 3 3 –
Anorexia 3 3 –
Muscle weakness 3 2 1
Febrile neutropenia 2 – 2
Extremity pain 2 2 –
Hypocalcemia 2 1 1
Increased creatinine 2 2 –
Limb edema 2 2 –
Nasal congestion 2 2 –
Headache 2 2 –
Peripheral neuropathy 2 2 –
Hematuria 2 2 –
Back pain 2 2 –
Skin hyperpigmentation 2 2 –
Molecular Therapy4-1BB27 may have deleterious effects on CARTs by leading to ligand-
independent tonic signaling, coexpression of both CD28 and 4-1BB
may compensate for the negative effects of single signaling.26,27 The
clinical data reported here show that expansion and persistence of
3G CD19.CARTs are superior to 2G CD19.CARTs in vivo, without
potential biases resulting from the comparison of distinct CARTs in
different patients. This difference was particularly striking in patients
with minimal residual disease and low numbers of circulating normal
CD19+ B cells, a patient subset for whom the benefits of 2G CD19
CAR may be limited by their poor expansion and persistence, and
the resulting small area under the curve.2732 Molecular Therapy Vol. 26 No 12 December 2018It is generally accepted that CD28 costimulation promotes rapid
expansion of CARTs upon antigen engagement, while 4-1BB costi-
mulation is critical in promoting their long-term persistence.20 Our
direct comparison of 2G versus 3G CD19.CARTs in lymphoma
patients with active disease suggests that the inclusion of 4-1BB
into 3G CD19.CARTs does not hamper the expansion kinetics
observed for 2G CD28-containing CD19.CARTs, but rather increases
the magnitude of their expansion. In fact, both 2G and 3G
CD19.CARTs showed peak expansion 2 weeks after infusion, but
CAR copy numbers were much higher for the 3G CD19.CARTs.
On the other hand, the presence of the CD28 in 3G CD19.CARTs
does not appear to compromise the ability of 4-1BB to support
long-term persistence of CD19.CARTs, as reported in other clinical
studies using only 4-1BB.28 Indeed, in our direct comparison, 3G
CD19.CARTs remained detectable at higher levels up to day 160
post-infusion as compared to 2G CD19.CARTs. Remarkably, when
2G and 3G CD19.CARTs were infused in patients in remission after
ASCT, a setting in which the cognate CD19-expressing cells are
absent or minimally present, only 3G CD19.CARTs showed sizeable
expansion at 2 weeks. This antigen-independent expansion of 3G
CD19.CARTs may be attributed to the increased numbers of
central memory CD4+ and CD8+ T cells in the 3G CD19.CARTs
but can also be explained by the previously described antigen-
independent proliferation in vitro of CD19.CARTs encoding the
4-1BB alone.27 Overall, combining CD28 and 4-1BB within the
same CD19.CAR may preserve the physiological effects of each
costimulatory molecules when used as a single domain while miti-
gating detrimental effects of either costimulation alone.
Despite high expansion and significant clinical responses, the rates
of severe toxicities in the active disease cohort were acceptable, and
tocilizumab was used in just one patient, to treat neurotoxicity.
Patients had responses (including CR) even with no clinical evidence
of CRS, showing that responses can occur even in the absence of
significant CRS. Although we investigated whether responses corre-
lated with CD19.CART dose infused, CART expansion, and blood
cell counts at infusion (total white blood cell, absolute lymphocyte,
and absolute neutrophil count), we could not demonstrate any
significant association between these parameters and response (data
not shown).
Even with these encouraging results, many potential barriers remain
in the path to universal responses to CART therapy. First, loss or
modulation of expression of the targeted antigen is a common mech-
anism of tumor escape, which has already been documented in
patients treated with 2G CD19.CARTs.29 This escape mechanism
may be particularly important with CARTs, since epitope spreading
to recruit other cytotoxic T cells has not yet been clearly demon-
strated, in contrast to the epitope spreading observed with native
TCR-mediated tumor killing.30,31 Certainly, we found no evidence
of cytotoxic T cell epitope spreading in the patients treated in this
study. The absence of epitope spreading to recruit additional cyto-
toxic responses may limit the generation of a sustained and broad
enough immune response to prevent antigen editing, tumor escape,
Figure 2. Patient #2 Achieved Durable CR after Infusion of CD19.CARTs
Patient #2 is a 67-year-old male who had primary refractory DLBCL arising in a background of follicular lymphoma and was unable to proceed to ASCT after two salvage
regimens. He was given lymphodepletion followed by CART infusion and, 10 days later, he developed fever (A) and tachypnea and was admitted to the hospital, where all
cultures remained negative. On admission, inflammatory markers, including CRP (peaking at 12.2 mg/dL on day 11) and IL-6 (peaking at 91.2 pg/mL on day 11 from
6.3 pg/mL at baseline) were elevated, consistent with mild CRS. At this point, we documented a 5-log expansion of his CART cells by genomic qPCR, corresponding to 25%
of circulating T cells by flow cytometry (B). In contrast to all other patients, the 2G CAR-T cells ultimately expandedmore. His symptoms resolved spontaneously in less than a
week while receiving conservative treatment and a repeat PET scan obtained 6 weeks after CART infusion showed CR (C), which has been sustained for more than
18 months.
www.moleculartherapy.organd incomplete eradication of tumors. Thus, the ability to obtain sub-
stantial expansion of 3G CD19.CARTs even in minimal residual
disease may be of value for avoiding relapse by CD19-negative variant
cells, since these will likely be more numerous in bulky compared to
minimal disease.
In conclusion, our comparison study of autologous 2G with 3G
CD19.CARTs shows that this strategy produces antitumor activity
while causing manageable toxicities and that the superior expansion
and persistence of the 3G vector may make it particularly suited to
the eradication of minimal residual disease.
MATERIALS AND METHODS
Clinical Study
We conducted a phase 1 study (NCT01853631) designed to assess the
feasibility and safety of treating patients with relapsed or refractory
aggressive or highly aggressive CD19-positive lymphoproliferative
disorders with escalating doses of autologous, polyclonally activated,
peripheral blood T cells that were genetically modified to express
a CD19-specific CAR (CD19.CAR). We infused two cell products
simultaneously in each patient, one transduced with a second-gener-
ation CD19-CAR (2G) containing one costimulatory domain (CD28)and another with a 3G CD19-CAR (3G) having both CD28 and
CD137 (4-1BB) costimulatory domains. Both constructs included
the CD3z endodomain. We treated patients in one of two settings:
with measurable disease at the time of infusion (active disease cohort)
or in radiological remission after high-dose therapy and autologous
stem cell transplant (post-ASCT cohort) (Figure 1). We gave patients
in the active disease cohort lymphodepleting doses of cyclophospha-
mide (500 mg/m2) and fludarabine (30 mg/m2) daily for 3 days,
finished 24 to 72 hr before administration of CD19.CARTs. We
administered three dose levels of CD19.CARTs, 1 106 (dose level 1),
5  106 (dose level 2), and 2  107 (dose level 3) CAR+ cells/m2 of
each CART population, with total cell numbers adjusted for the per-
centage of CAR+ cells in the final products. We infused both cell pop-
ulations intravenously over 2–5 min with a 5- to 10-min interval
between them. We used an interpatient dose escalation that followed
a continual reassessment method, which required safety to be demon-
strated 6 weeks after infusion in two patients at each dose level before
escalation. We allowed additional infusions at least 6 weeks apart of
the same dose of CD19.CARTs without lymphodepleting chemo-
therapy as long as there was evidence of clinical benefit, defined as
at least stable disease. We performed clinical and laboratory evalua-
tion at weeks 1, 2, 4, and 6, months 3, 6, 9, and 12 post-CARTMolecular Therapy Vol. 26 No 12 December 2018 2733
Figure 3. Patients #4 and #16 Achieved CR after Infusion of CD19.CARTs
(A) Patient #4 is 64-year-old female with DLBCL transformed from ENMZL, which had relapsed a few months post-high-dose-therapy and ASCT. At this point, she received
lymphodepleting chemotherapy followed by CART cells. Notably, she did not develop any clinically apparent CRS, but a repeat PET scan 6 weeks after infusion was
consistent with CR, which has beenmaintained formore than 12months. (B) Patient #16 is a 52-year-oldmale with de novoDLBCL, which relapsed 3months after high-dose
therapy and ASCT and was refractory to two second-line chemotherapy regimens and led to gastric outlet obstruction syndrome. The patient received lymphodepleting
chemotherapy followed by CART cells, developed mild CRS within 1 week, and a repeat PET scan 6 weeks after infusion demonstrated a dramatic CR. Expansion data for
each patient is shown on the bottom row.
Molecular Therapyinfusion, and yearly thereafter. We graded adverse events during and
after T cell infusions according to the NIH Common Terminology
Criteria for Adverse Events (CTCAE), version 4 (https://ctep.
cancer.gov/). We assessed responses by imaging and pathology
studies, as applicable, at week 6 after CART infusion. For NHL, we
defined complete response (CR), partial response (PR), stable disease
(SD), and progressive disease (PD) according to the revised response
criteria for malignant lymphomas of the International Working
Group.32 For patients who had exclusively bone marrow disease at
the time of treatment, we defined CR as having no tumor cells detect-
able on bone marrow aspirate and biopsy, PR as at least halving the2734 Molecular Therapy Vol. 26 No 12 December 2018amount of tumor in the marrow compared to the level present at
study entry, PD as doubling of the amount of tumor in the marrow,
and SD as not meeting criteria for any of the other categories.
Generation of Retroviral Constructs
We have previously described the 2G vector.2 We cloned an identical
single chain variable fragment (scFv) to generate the 3G CAR
construct containing both CD28 and 4-1BB (CD137) endodomains,
including a spacer region derived from the human immunoglobulin
G1 (IgG1)-CH2CH3 domains in frame between the scFv and the
signaling domains to facilitate detection by phenotypic analysis of
www.moleculartherapy.orgthe transgenic product. We then cloned this cassette into the SFG
retroviral backbone. We generated the clinical grade packaging cell
line using PG13 cells (gibbon ape leukemia virus pseudotyping pack-
aging cell line; American Type Culture Collection CRL-10686).33 We
used the highest-titer clones to establish master cell banks and
released them for clinical use only after safety testing and vector
sequencing. We stored the final viral supernatant at80C and tested
it before clinical release.Generation and Transduction of CD19.CARTs
To generate both CD19.CART products (2G and 3G), we transduced,
independently but in parallel, PBMCs prepared by Ficoll density
centrifugation of peripheral blood obtained by phlebotomy 1 to
3 months before CART administration. We activated PBMCs in
24-well plates coated with CD3 and CD28 antibodies (Miltenyi
Biotec, Cambridge, MA) and containing interleukin-7 (IL-7)
(10 ng/mL, R&D Systems, Minneapolis, MN) and IL-15 (5 ng/mL,
R&D Systems, Minneapolis, MN), for 24 to 72 hr. At the time of
transduction, we transferred the activated PBMCs to 24-well plates
coated with a recombinant fibronectin fragment (FN CH-296, Retro-
nectin Takara, Clontech, Mountain View, CA). After transduction,
T cells were expanded ex vivo in the presence of IL-7 (10 ng/mL)
and IL-15 (5 ng/mL), added twice a week.34 Generation of each of
the 56 CD19.CART products required a median of 10 days (range
9–14 days) of culture.Immunophenotyping
We used phycoerythrin (PE)-, fluorescein isothiocyanate (FITC)-,
peridinin chlorophyll protein (PerCP)-, or allophycocyanin (APC)-
conjugated CD3, CD4, CD8, CD56, CD19, TCR-ab, TCR-gd,
CD62L, CD27, CD28, CD45RA, CD45RO, CCR2, CCR4, CCR5,
CCR7, CXCR3, CXCR4, CD162, CD54, CD38, CD106, CD11a,
CD11c, and CD18 (Becton Dickinson-PharMingen, San Diego, CA)
antibodies to stain the T cell products or tumor cells. We included
control samples labeled with appropriate isotype-matched antibodies
in each experiment. We detected the CD19.CAR with an Fc-specific
Alexa Fluor 647-conjugated goat polyclonal F(ab’)2 fragment anti-
human IgG (Jackson ImmunoResearch, West Grove, PA), which rec-
ognizes the IgG1-CH2CH3 component of the CAR. We analyzed the
cells by FACScan or FACSCanto II (BectonDickinson) equipped with
a filter set for four fluorescence signals, using CellQuest software.
Data analysis was performed using FlowJo (Treestar, Ashland, OR)
or Kaluza (Beckman Coulter, Indianapolis, IN) software.Cytotoxicity Assays
The cytotoxic specificity of each T cell line was measured in a stan-
dard 4-hr 51Cr release assay, using effector-to-target (E:T) ratios of
40:1, 20:1, 10:1, and 5:1. As targets, we used Daudi and Raji
(CD19+ tumor cells), HDLM-2 (CD19 tumor cells), and K562 (nat-
ural killer [NK]-sensitive) cells. Target cells were labeled simulta-
neously for 1 hr with 51Cr. We calculated the percentage of specific
lysis as ([experimental release  spontaneous release]/[maximum
release  spontaneous release])  100.Real-Time qPCR of CD19.CAR Transgene
We quantified the integrated genome of the retrovirus encoding the
CD19.CAR by real time qPCR.2 After extracting DNA from periph-
eral blood samples with the QIAampDNABloodMini Kit (QIAGEN,
Hamburg, Germany), we amplified the DNA with specific primers
and TaqMan probes (Applied Biosystems, Foster City, CA) comple-
mentary to specific sequences within the 2G and 3G retroviral
vectors.35 We performed amplifications using the ABI7900HF
(Applied Biosystems) cycler. The baseline range was set at cycles
6–15, with the threshold at 10 standard deviations above the
baseline fluorescence. The standard curve was established using serial
dilutions of the plasmid encoding the transgene. DNA integrity was
assessed using a PCR assay for the b-actin gene.
Cytometric Bead Array and Multiplex Assays
We analyzed plasma or serum samples collected before and after
CD19.CART infusion using a BD cytokine cytometric bead array
(CBA) kit (Becton Dickinson-PharMingen) or a Milliplex kit (EMD
Millipore, Billerica, MA). In parallel with the samples, we used the
human cytokine standards provided with the kit to prepare standard
curves. We ran the CBA assays using the FACS Calibur (Becton
Dickinson-PharMingen) and analyzed data from the Milliplex kits
using the Luminex 200 System and the Milliplex Analyst Software
(EMD Millipore).
Statistics
We used descriptive statistics (means, median, ranges, and standard
deviations, or standard errors) to summarize the data. We calculated
the area under the curve (AUC) for CAR-T cell expansion using the
trapezoidal rule. A log transformation was performed to achieve
normality if appropriate. Student’s t test was used for between-group
comparisons, while the paired t test was applied for within-subject
comparisons. A p value less than 0.05 was considered statistically
significant.
Study Approval
This study was approved by the United States Food and Drug
Administration, the Recombinant DNA Advisory Committee, and
the Institutional Review Board of Baylor College of Medicine and
was conducted in accordance with the Declaration of Helsinki. All
participants gave informed consent on enrollment.
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